[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,73,100,127,149,174,194,214,256,277,297,318,339,360,379],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100577341","proof-of-concept-to-assess-the-feasibility-of-a-decentralised-pathway-coordinated-by-the-advanced-practice-nurse-for-patients-receiving-oral-treatment-for-cancer-or-malignant-haemopathy-acceler-platform-100577341",false,"NCT06797037","Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)","Inclusion Criteria:\n\n1. Patient over 18.\n2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management.\n3. Patient with a performance index (ECOG): 0-2.\n4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse.\n5. Patient willing to make two home visits within 6 months of inclusion.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding patient.\n2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol.\n3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.","ALL","18 Years",{"count":18,"type":19},33,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is an open-label, single-centre, category 2 \"Jardé Law\" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral treatment.\n\nThe study will be conducted on a population of 33 patients.\n\nIn current practice, patients with certain solid cancers or haematological malignancies may be prescribed oral chemotherapy on a retroceded basis. In these cases, the oncologist (coordinating investigator) sees the patient for a consultation every 3 cycles to prescribe\u002Frenew the treatment for approximately 3 months. Every month, the patient returns to the centre to have the treatment dispensed by the hospital pharmacy. No medical consultation is associated with this visit.\n\nIn this study, it is proposed to decentralise the delivery of treatment to these patients by introducing two visits to the patient's home by a service-providing nurse.\n\nThe decentralised patient pathway will be organised and monitored by the Advanced Practice Nurse (APN) at the investigating centre, who will be responsible in particular for coordination with the service-providing nurse and the hospital pharmacy.",[25,26],"Solid Cancer","Haematological Malignancies",[28],"Retroceded oral chemotherapy","RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2025-05-19",{"date":37,"type":19},"2027-05-19",{"name":39,"class":40},"Institut Claudius Regaud","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100528457","phase-2-a-study-of-raludotatug-deruxtecan-r-dxd-in-subjects-with-platinum-resistant-high-grade-ovarian-primary-peritoneal-or-fallopian-tube-cancer-100528457","NCT06161025","A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","A Phase 2\u002F3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Inclusion Criteria:\n\n* Sign and date the informed consent form prior to the start of any study-specific qualification procedures.\n* Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.\n* Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer.\n* For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen.\n* For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy:\n\n  * Neoadjuvant +\u002F-adjuvant considered 1 line of therapy.\n  * Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase \\[PARP\\] inhibitors) will be considered part of the preceding line of therapy.\n  * Therapy changed due to toxicity in the absence of progression will be considered part of the same line.\n  * Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance.\n  * At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions\u002Fintolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study.\n* Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between \\>90 and ≤180 days after the date of the last dose of platinum If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.\n* If mirvetuximab soravtansine (MIRV) is locally available: Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions\u002Fintolerance, or if the treatment is not approved or available locally.\n* Has at least 1 measurable lesion evaluated by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator assessment.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Has adequate organ and bone marrow function as assessed by local laboratory (within 14 days before start of study drug administration).\n* Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions.\n* For Phase 3 (Part B) only: Subjects must be eligible for one of the treatments included in the investigator's choice of chemotherapy arm.\n\nExclusion Criteria\n\n* Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade\u002Fborderline OVC. (Note for Phase 3 \\[Part B\\]: seromucinous, low-grade serous carcinoma or ovarian sarcoma, carcinosarcoma and undifferentiated carcinoma are excluded.)\n* Inadequate washout period before Cycle 1 Day 1, defined as follows:\n\n  * Major surgery \\\u003C28 days\n  * Radiation therapy \\\u003C28 days (if palliative stereotactic radiation therapy without abdominal radiation, ≤14 days)\n  * Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) \\\u003C28 days or 5 half-lives, whichever is shorter, before starting study drug\n  * Chloroquine\u002Fhydroxychloroquine \\\u003C14 days\n  * Exposure to another investigational drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures\n* Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion A minimum of 2 weeks must have elapsed between the end of radiotherapy and randomization and there should be no evidence of progression or need for steroid treatment or anticonvulsants for at least 2 weeks prior to randomization. Note: If there is a history or suspicion of central nervous system. Note: If there is a history or suspicion of central nervous system metastasis, a CT scan of the head or MRI of the brain must be performed at baseline.\n* Any of the following within the past 6 months prior to randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.\n* Uncontrolled or significant cardiovascular disease, including the following:\n\n  * QT interval corrected with Fridericia's formula interval \\>470 ms.\n  * Diagnosed or suspected long QT syndrome.\n  * History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.\n  * The participant has bradycardia of less than 50 bpm, unless the subject has a pacemaker.\n  * History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.\n  * Myocardial infarction within 6 months prior to screening.\n  * Uncontrolled angina pectoris within 6 months prior to screening.\n  * New York Heart Association Class 3 or 4 congestive heart failure.\n  * Left ventricular ejection fraction \\\u003C50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan.\n  * Coronary\u002Fperipheral artery bypass graft within 6 months prior to screening\n  * Uncontrolled hypertension (HgCTCAE Grade ≥3 hypertension as per NCI-CTCAE version 5.0).\n  * Complete left or right bundle branch block.\n* Has a history of (noninfectious) ILD\u002Fpneumonitis that required corticosteroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, etc) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy.\n* Chronic steroid treatment (\\>10 mg\u002Fday), with the exception of the following:\n\n  * Inhaled steroids for asthma or COPD\n  * Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension\n  * Topical steroids for mild skin conditions\n  * Low-dose supplemental corticosteroids for adrenocortical insufficiency\n  * Premedication for treatment groups and\u002For premedication in case of any hypersensitivity\n  * Intra-articular steroid injections\n* History of malignancy other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate \\>90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer).\n* Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade ≤1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade \\>2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following:\n\n  * Chemotherapy-induced neuropathy\n  * Fatigue\n  * Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency\n  * Skin pigmentation (vitiligo)\n* For Phase 2 (Part A): Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor.\n* History of hypersensitivity to any excipients in the R-DXd or any known contraindication to treatment with, including hypersensitivity to, the study drug(s).\n* Has an active or uncontrolled human immunodeficiency virus (HIV) infection.\n* Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.\n* Has an active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Hepatitis B and Hepatitis C Screening tests are required.\n\nSubjects are eligible if:\n\n1. Hepatitis B virus surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n2. History of hepatitis C infection: eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks.\n3. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HCV infection.\n\n   * Female who is pregnant or breastfeeding or intends to become pregnant during the study.\n   * Psychological, social, familial, or geographical factors that would prevent regular follow-up.\n   * Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.\n   * Has a history of receiving live-attenuated vaccine (messenger RNA \\[mRNA\\] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.\n   * For Phase 3 (Part B) only: Has clinical symptoms or radiographic evidence of intestinal obstruction.\n   * For Phase 3 (Part B) only: Has ascites or pleural effusions that require repeated drainage (less than 4 weeks between drainages).",{"count":50,"type":19},860,[52,53],"PHASE2","PHASE3","This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.",[25],[57,58,59,60,61],"Primary pertioneal cancer","Ovarian cancer","Fallopian tube cancer","Raludotatug Deruxtecan (R-DXd)","Cadherin 6 (CDH6)","2026-05-20",{"date":64,"type":33},"2026-05-22",{"date":66,"type":33},"2024-02-27",{"date":68,"type":19},"2030-04-30",{"name":70,"class":71},"Daiichi Sankyo","INDUSTRY",146,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100633242","phase-1-study-of-ze94-0605-in-patients-with-advanced-solid-tumors-with-dose-expansion-cohorts-100633242","NCT07524140","Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.","Phase 1 Study of ZE94-0605 in Solid Tumors Who Have Exhausted All Treatment Options and Then With Expansion Into Two Dose Cohorts in Select Solid Tumor Patients","Inclusion Criteria:\n\n1. Phase 1 Escalation cohort:\n\n   Patients ≥ 18 with pathologically confirmed, advanced and unresectable or metastatic solid tumor refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.\n\n   Phase 1 Expansion cohort:\n\n   Patients ≥ 18 with pathologically confirmed, advanced and unresectable or metastatic solid tumor refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition or who have declined it who have CCNE1 amplification.\n2. ECOG performance status of 0-1.\n3. Adequate end-organ function as defined by: Creatinine clearance \\>60 ml\u002Fmin, AST\u002FALT \\\u003C3x upper limit of normal, total bilirubin \\\u003C1.5x upper limit of normal (except for patients with Gilbert's disease).\n4. Absolute Neutrophil Count (ANC) must be 1.5 x 109\u002FL or greater, platelets 100 x 109\u002FL or greater.\n5. For female patients of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the screening visit throughout the study treatment period and for 30 days following the last dose of either study drug.\n6. For male patients of childbearing potential having intercourse with females of childbearing potential, the willingness to abstain from heterosexual intercourse or use a protocol recommended method of contraception from the start of study treatment throughout the study treatment period and for 90 days following the last dose of either study drug. Males must also refrain from sperm donation from the start of study treatment throughout the study treatment period and for 90 days following the last dose of either dose of study drug.\n7. Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures and study restrictions.\n\nExclusion Criteria:\n\n1. History of alternative malignancy except for the following: adequately treated local basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease or any other cancer that has been in complete remission without treatment for ≥ 2 years prior to enrollment or that has life expectancy of 24 months and does not require therapy that confounds interpretation of data from this study. Cases where this occurs must be discussed with the medical monitor before screening for enrollment.\n2. Known active Hepatitis C, Hepatitis B, or HIV.\n3. Pregnancy or breast feeding.\n4. Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 14 days prior to study treatment.\n5. Inability to tolerate oral medications including symptomatic disease significantly affecting gastrointestinal function such as inflammatory bowel disease or resection of stomach or small bowel.\n6. Patients who have received an investigational agent (for any indication) within 5 half-lives of the agent; if the half-life of the agent is unknown, patients must wait 1 week prior to first dose of study treatment. An investigational agent is one for which there is no approved indication by the United States (US) FDA.\n7. Patients with psychological, familial, social, or geographic factors, other significant medical condition, laboratory abnormality that otherwise preclude them from giving informed consent, following the protocol, potentially hamper compliance with study treatment and follow-up or would confound the interpretation of the results of the trial.\n8. Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, New York Heart Association (NYHA) Class III or IV heart failure, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Patients with medical comorbidities that will preclude safety evaluation of the combination should not be enrolled.\n9. Patients with QTc greater than or equal to 470ms unless patient has a pacemaker. Patients with an incomplete or complete right\u002Fleft bundle branch block may participate if cleared by a cardiology evaluation for enrollment.",{"count":81,"type":19},60,[83],"PHASE1","Phase 1 Study of ZE94-0605 in solid tumors who have exhausted all treatment options and then with expansion into two dose cohorts in select solid tumor patients.",[86,25,87],"Solid Tumor Malignancies","Metastatic Solid Tumor",[89,87],"CDK2 inhibitor","NOT_YET_RECRUITING","2026-04-06",{"date":93,"type":33},"2026-04-13",{"date":95,"type":19},"2026-04",{"date":97,"type":19},"2028-05",{"name":99,"class":71},"Eilean Therapeutics",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":20,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100611579","early-phase-1-tc-g203-for-patients-with-gpc3-positive-advanced-solid-tumors-100611579","NCT07242417","TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors","A Preliminary Clinical Study of TC-G203 for Patients With GPC3-Positive Recurrent\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Participants must voluntarily provide written informed consent.\n2. Aged 18-75 years (inclusive).\n3. Life expectancy ≥ 12 weeks.\n4. ECOG performance status 0-1.\n5. Failed or unsuitable for standard therapy.\n6. At least one measurable lesion per RECIST 1.1.\n7. GPC3-positive tumor confirmed by immunohistochemistry.\n8. Adequate organ and bone marrow function.\n9. Effective contraception required for participants of childbearing potential.\n10. Adequate venous access for leukapheresis.\n\nExclusion Criteria:\n\n1. Primary CNS malignancy or uncontrolled CNS metastases.\n2. Other malignancies within 5 years\n3. Active autoimmune disease or history of autoimmune disease.\n4. Immunodeficiency, including HIV positivity\n5. Bleeding disorders (inherited or acquired).\n6. Clinically significant cardiovascular disease.\n7. Active infection (including tuberculosis, hepatitis C, syphilis).\n8. Pregnant or breastfeeding women.\n9. Severe systemic or psychiatric illness.\n10. Prior cell or gene therapy.\n11. Severe drug hypersensitivity history.\n12. Investigator-assessed unsuitability for trial participation. -","75 Years",{"count":109,"type":19},30,[111],"EARLY_PHASE1","This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.",[25,114],"GPC3 Positive Hepatocellular Carcinoma",[25,116],"GPC3 positive hepatocellular carcinoma","2026-01-19",{"date":119,"type":33},"2026-01-21",{"date":121,"type":33},"2025-12-18",{"date":123,"type":19},"2027-11-01",{"name":125,"class":40},"Beijing GoBroad Hospital",2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100612790","phase-2-evaluation-of-the-effect-of-cordycepin-on-cd8-lymphocytopenia-in-patients-with-solid-tumors-100612790","NCT07258160","Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors","Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors: A Randomized Withdrawal Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Participants with solid malignant tumors, with confirmed pathological diagnosis or medical history; they have completed radiotherapy and\u002For chemotherapy more than six months ago; and peripheral blood CD8+ absolute count (blood drawn before 10:00 AM) below the lower reference limit (LRL);\n3. No treatment with immunomodulatory or immunosuppressive agents within the past 2 weeks prior to enrollment;\n4. ECOG performance status score of 0-1, with an estimated life expectancy of ≥ 3 months;\n5. AST and ALT ≤ 3.0 times the upper limit of normal (ULN) within one week prior to study enrollment; serum creatinine ≤ 2 times ULN;\n6. Ability to understand the study and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n1. History of uncontrolled epilepsy, central nervous system (CNS) disease, or mental disorders, as determined by the investigator to be clinically significant and potentially interfere with the participant's ability to provide informed consent or comply with medication;\n2. Significant (i.e., active) cardiovascular disease, including symptomatic coronary heart disease, congestive heart failure classified as New York Heart Association (NYHA) Class II or worse, or serious arrhythmias requiring pharmacological intervention, or history of myocardial infarction within the past 12 months;\n3. Known active serious infections, or in the investigator's opinion, presence of major hematological, renal, metabolic, gastrointestinal, or endocrine dysfunction, or other serious, uncontrolled comorbidities;\n4. History of allergy to fungi, or to any of the following components: Cordyceps militaris extract powder, D-mannitol, maltitol, microcrystalline cellulose, or magnesium stearate;\n5. History of immunodeficiency, including HIV positive status, or diagnosis with other acquired or congenital immunodeficiencies, or a history of organ transplantation, or immunological disorders requiring long-term oral corticosteroid treatment;\n6. Acute gout flare\n7. Any other condition deemed unsuitable for enrollment by the investigator.",{"count":135,"type":19},127,[52],"The goal of this clinical trial is to evaluate the effectiveness of PRaG-1 in improving CD8+ lymphocytopenia in patients with solid tumors who are tumor-free for more than six months after completing radiotherapy and\u002For chemotherapy. It will also assess the safety of PRaG-1 Cordycepin in these patients. The main questions it aims to answer are:\n\nDoes PRaG-1 increase CD8+ lymphocyte counts by more than 25% in this patient population? Does the effect of PRaG-1 maintain when treatment is discontinued? What are the safety and tolerability profiles of PRaG-1 during and after the treatment period? Participants will receive open-label PRaG-1 (one tablet in the morning and one in the evening) for 14 days, and those who show a response (CD8+ lymphocytes increase by more than 25%) will enter a 14-day randomized withdrawal period, where they will be assigned to continue PRaG-1 or switch to a placebo.\n\nThroughout the study, participants will:\n\nHave their peripheral blood lymphocyte subpopulations tested at baseline and on Days 7 and 14 Undergo safety monitoring for adverse events according to CTCAE 5.0 criteria Provide information on their quality of life during the treatment period Researchers will compare the outcomes of those who continue PRaG-1 to those who receive a placebo to determine if the observed improvement in CD8+ lymphocytes is sustained, which would indicate that the drug is effective in maintaining immune response.",[25,139],"Lymphopenia","2026-01-07",{"date":142,"type":33},"2026-01-09",{"date":144,"type":33},"2025-12-01",{"date":146,"type":19},"2026-09",{"name":148,"class":40},"Second Affiliated Hospital of Soochow University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":20,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100605345","urolithin-a-in-patients-with-previously-untreated-solid-tumors-receiving-immune-checkpoint-inhibitors-100605345","NCT07161310","Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors","A Randomized Study of Urolithin A vs. Placebo in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors","MitoCancer","Inclusion Criteria:\n\n1. Newly diagnosed solid cancer without previous systemic anticancer treatment\n2. Planned single agent or double agent immune checkpoint inhibitor therapy as first-line standard-of-care treatment either with or without chemotherapy. Of note, patients receiving neoadjuvant therapy are eligible\n3. Age ≥ 18 years\n4. Life-expectancy ≥ 3 months\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n6. Patient is willing and able to comply with the protocol for the duration of the study, including hospital visits and scheduled follow-up visits and examinations\n7. Female patients of childbearing potential (WOCBP) are only eligible if using highly effective contraceptive measures and must have a negative urine or serum pregnancy test within 7 days prior to start of study treatment and must not be breast-feeding prior to start of trial. Non-child-bearing potential must be evidenced by fulfilling one of the following criteria at screening:\n\n   * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n   * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.\n   * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n\nExclusion Criteria:\n\n1. Patients who currently receive or have received cytostatic chemotherapy, glucocorticoids, or immune modulatory agents (including low-dose methotrexate, TNF alpha inhibitors, calcineurin inhibitors, interleukin inhibitors, etc.) during the last 3 months are not eligible. Of note, topical glucocorticoid treatments and hormone replacement therapy is acceptable\n2. Patients who currently take or plan to take mitochondrial supplements like coenzyme q10, NAD+ boosters (e.g. nicotineamide riboside, nicotineamine mononucleotide), or L-carnitine\n3. Patients who have received radiotherapy to the mediastinum or to other areas with anticipated strong irradiation of a large blood vessel by the judgement of the investigator are not eligible\n4. Patients with known HIV infection are not eligible. Testing is not mandatory\n5. Patients with a history of solid organ or hematopoietic cell transplantation6. Any medical condition that in the opinion of the investigators would compromise the study outcome or the safety of the patient",{"count":158,"type":19},45,[22],"The aim of this clinical study is to learn more about the effects of urolithin A (MitoPure®) on the immune system of cancer patients receiving immune checkpoint inhibitor-based therapies. Any effects will be compared with patients who take a placebo instead of urolithin A (MitoPure®).",[25,162,163],"Non-Small Cell Lung Cancer","Melanoma",[165],"immune checkpoint inhibitor (ICI)",{"date":167,"type":33},"2026-01-08",{"date":169,"type":33},"2026-01-02",{"date":171,"type":19},"2027-03",{"name":173,"class":40},"Goethe University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":107,"enrollmentInfo":181,"targetDuration":4,"studyType":20,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100614571","phase-1-a-study-of-ak138d1-in-advanced-malignant-tumors-100614571","NCT07281326","A Study of AK138D1 in Advanced Malignant Tumors","A Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AK138D1 in Advanced Solid Tumors","Inclusion Criteria:\n\n1. The subject must sign the written informed consent form (ICF) voluntarily;\n2. At enrollment, aged ≥ 18 to ≤ 75 years, both males and females are eligible;\n3. ECOG performance status score of 0 or 1;\n4. Has a life expectancy of ≥ 3 months;\n5. At least 1 measurable lesion as per RECIST v1.1 that is suitable for repeated accurate measurement.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Prior human epidermal growth factor receptor 3 (HER3) -targeted therapies, including antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell immunotherapy (CAR-T), and others;\n2. Concomitant participation in another clinical study, unless it is a non-interventional clinical study or the follow-up period of an interventional study;\n3. Presence of active central nervous system (CNS) metastases.\n4. Live vaccines or attenuated live vaccines administered within 4 weeks prior to the first dose, or planned to be administered during the study; use of inactivated vaccines is allowed;\n5. Untreated subjects with active hepatitis B or active hepatitis C;\n6. Known active pulmonary tuberculosis (TB); subjects with suspected active TB must undergo appropriate clinical assessment to rule out the presence of active disease;\n7. Known active syphilis infection;\n8. Subjects with known allergy to any component of any study drug; and with a history of known severe hypersensitivity reactions to other monoclonal antibodies;\n9. Other reasons for ineligibility as evaluated by the investigator.",{"count":182,"type":19},200,[83],"This is a Phase I clinical trial testing the safety and effectiveness of AK138D1in patients with advanced cancer. The study will enroll up to 200 patients with various types of advanced solid tumors who haven't responded to standard treatments. Patients will receive AK138D1 to determine the safest dose and evaluate if the drug can help treat their cancer.",[25],{"date":187,"type":33},"2025-12-15",{"date":189,"type":33},"2025-10-22",{"date":191,"type":19},"2028-05-30",{"name":193,"class":71},"Akeso",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":20,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100613487","phase-2-prag-1-plus-prag-therapy-in-advanced-solid-tumors-a-prospective-clinical-trial-prag-100-100613487","NCT07267234","PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically confirmed treatment-naïve or relapsed\u002Fmetastatic advanced solid malignancies with no standard treatment option per current clinical guidelines or intolerance to standard therapy; measurable metastatic lesions ≥1 cm (by RECIST criteria); absolute lymphocyte count (ALC) below lower limit of normal (LLN).\n3. No history of congestive heart failure, unstable angina, or unstable cardiac arrhythmias within the past 6 months.\n4. ECOG performance status 0-3; estimated life expectancy ≥3 months.\n5. No history of significant hematologic, cardiac, pulmonary, hepatic, or renal dysfunction.\n6. Baseline AST ≤3×ULN and ALT ≤3×ULN (≤5×ULN for hepatocellular carcinoma or liver metastases); creatinine ≤3×ULN.\n7. Capacity to comprehend study procedures and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n1. History of other malignancies within the past 5 years, except for adequately treated non-melanoma skin cancer or cervical carcinoma in situ.\n2. Uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders that, in the investigator's judgment, may interfere with informed consent or treatment adherence.\n3. Clinically significant active cardiac disease, including symptomatic coronary artery disease, NYHA Class II or higher congestive heart failure, severe arrhythmias requiring pharmacological intervention, or myocardial infarction within the past 12 months.\n4. History of solid organ transplant requiring ongoing immunosuppressive therapy.\n5. Known significant active infection, or significant hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction, or other serious uncontrolled comorbidities as determined by the investigator.\n6. Allergy to any component of the study drug(s).\n7. History of immunodeficiency, including HIV infection, acquired or congenital immunodeficiency disorders, solid organ transplant, or chronic immunosuppressive therapy for immune-related conditions.\n8. Active or latent tuberculosis infection confirmed by positive T-SPOT.TB test or chest X-ray findings suggestive of tuberculosis.\n9. Any other condition that, in the investigator's clinical judgment, may compromise study participation or safety.",{"count":201,"type":19},65,[52],"The goal of this clinical trial is to learn if a combination treatment using PRaG-1 Cordycepin Tablets with radiation therapy, immune-boosting injections, and immunotherapy drugs can help patients with advanced solid tumors. It will also assess safety. The main questions it aims to answer are:\n\nDoes this treatment improve immune function and slow tumor growth? What side effects or risks occur during treatment?\n\nParticipants will:\n\nTake PRaG-1 Cordycepin Tablets (a natural compound derived from Cordyceps fungus) orally: higher dose for 7 days before radiation, then lower daily dose for 2 weeks Receive targeted radiation therapy to the tumor area (5-12 Gy total in 2-3 sessions) Get daily immune-boosting injections (GM-CSF) for 7 days starting with radiation Receive immunotherapy drugs (PD-1\u002FPD-L1 inhibitors) within one week after radiation Have blood drawn and small tumor tissue samples taken before and after the first two treatment cycles for immune analysis All participants will receive this combination treatment; there is no placebo or alternative treatment group in this study.",[25,139,205,206],"Radiotherapy","Immune Checkpoint Inhibitor","2025-11-24",{"date":209,"type":33},"2025-12-05",{"date":144,"type":19},{"date":212,"type":19},"2027-09-01",{"name":148,"class":40},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":222,"targetDuration":224,"studyType":225,"phases":4,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":41},"100601756","impact-of-ces1-genotype-on-capecitabine-exposure-in-cancer-patients-100601756","NCT07114627","Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients","Exploratory Study of Capecitabine Pharmacokinetics and Hand-foot Syndrome in CES1 Variant Carriers: the ESCAPE Study","ESCAPE","In order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* 18 years of age or older;\n* Planned to start treatment with concomitant capecitabine and oxaliplatin according to standard of care (irrespective of dose);\n* Fit for treatment with capecitabine and oxaliplatin as judged by the treating physician;\n* Capable of understanding and complying with protocol requirements and able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Carrier of a known clinically relevant DPYD variant (i.e. \\*2A, \\*7, \\*13, c.1236G\\>A or c.2846A\\>T);\n* Any medical condition that is known to influence capecitabine absorption (i.e. a Roux-en-Y gastric bypass operation or complete gastric resection; an esophagectomy is not considered to impair absorption);\n* Prior treatment with fluoropyrimidines;\n* Use of DPD-inhibitors and\u002For allopurinol;\n* Known pregnancy at baseline.",{"count":223,"type":19},66,"2 Years","OBSERVATIONAL","In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form. In the body, capecitabine is converted into the active molecule that has anti-cancer effects. This molecule is called 5-FU. The transformation of capecitabine to 5-FU occurs through specific proteins in the liver, also known as enzymes.\n\nUnfortunately, capecitabine can also cause side effects. One of the most common side effects is hand-foot syndrome. In hand-foot syndrome, the palms of the hands and soles of the feet become red and painful. Previous research has shown that patients in whom one of the enzymes responsible for converting capecitabine in the liver does not function properly experience an increase in side effects frequency, particularly severe hand-foot syndrome. This specific enzyme is called CES1. It is believed that side effects occur more frequently because capecitabine is transformed more slowly, eventually leading to a prolonged exposure to 5-FU in the body.\n\nIn roughly one in three people, this enzyme functions less efficiently. To gain a better understanding of how this mechanism works, we aim to conduct this study. In this study, we will examine if patients with a less effective CES1 enzyme have higher amounts of 5-FU in their blood. We will also look into whether these patients develop side effects, such as hand-foot syndrome, more frequently. This information could eventually help us develop new strategies to reduce side effects for these patients in the future.",[25,228,229,230],"Gastric (Cardia, Body) Cancer","Esophageal Cancer","Colorectal Cancer (CRC)",[232,233,234,235,236,237,238,239,240,241,242,243,244,245,246],"CAPOX","CES1","carboxylesterase 1","Capecitabine","Pharmacokinetics","Pharmacogenetics","Oncology","SNP","Single-nucleotide polymorphism","rs2244613","Hand-foot syndrome","HFS","5-FU","ErasmusMC","Cancer","2025-08-04",{"date":249,"type":33},"2025-08-11",{"date":251,"type":33},"2025-02-18",{"date":253,"type":19},"2027-06",{"name":255,"class":40},"Erasmus Medical Center",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":263,"targetDuration":224,"studyType":225,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100596875","impact-of-interventional-endoscopy-on-quality-of-life-in-patients-with-acute-respiratory-distress-due-to-tumor-compression-or-obstruction-of-the-lower-respiratory-tract-100596875","NCT07051161","Impact of Interventional Endoscopy on Quality of Life in Patients With Acute Respiratory Distress Due to Tumor Compression or Obstruction of the Lower Respiratory Tract","ENDoRA","Inclusion Criteria:\n\n* \\>18 years old\n* tumoral tracheobronchial obstruction and\u002For compression\n* proven solid cancer or suspicion\n* Acute respiratory distress (at least one of the 5):\n\n  * RR : ≥25\u002Fmin\n  * Sign of respiratory struggle\n  * Sign of respiratory failure\n  * Oxygen therapy ≥5L\u002Fmin\n  * Ventilatory support (NIV, OHD or IT) :\n* Indication for therapeutic interventional endoscopy\n* No guardianship or curatorship\n* Non-hematological tumor\n\nExclusion Criteria:\n\n* Minors\n* patients with neurological disabilities unable to understand and respond to the questionnaire\n* patients under guardianship or curatorship",{"count":81,"type":19},"Bronchoscopic endoscopy has shown its effectiveness and reliability for the treatment (desobstruction or prothesis) of tumor-induced bronchial obstructions, particularly in the first few weeks. The presence of a lower airway prosthesis can lead to device obstruction requiring daily inhaled fluidification, bacterial colonization, migration of the prosthesis, or the appearance of obstructive or hemorrhagic granulomas.\n\nThe aim of this study is to evaluate the quality of life of patients after endobronchial treatment.\n\nIt is a prospective, descriptive, and multicentric (national) study. The main objective is to compare the total score on the Saint-George questionnaire at J7 of the interventional endoscopy compared to before the procedure.",[25,266,267],"Bronchial Endoscopy","Therapeutic Bronchofiberscopy","2025-06-26",{"date":270,"type":33},"2025-07-04",{"date":272,"type":19},"2025-08-01",{"date":274,"type":19},"2026-12-01",{"name":276,"class":40},"University Hospital, Grenoble",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":20,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100593135","phase-2-immune-modulation-with-prag-1-treatment-100593135","NCT07002502","Immune Modulation With PRaG-1 Treatment","Immune Modulation and Efficacy Assessment of PRaG-1 in Patients With Advanced Solid Malignancies: A Prospective, Multicenter, Open-Label Clinical Trial","Inclusion Criteria:\n\nPatients with a history of other malignant diseases within the past 5 years, except for curatively treated skin cancer and cervical carcinoma in situ; Patients with a history of uncontrolled epilepsy, central nervous system diseases, or psychiatric disorders, which, in the judgment of the investigator, may impair the ability to sign the informed consent form or affect the patient's compliance with drug treatment; Clinically significant (i.e., active) cardiovascular disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) Class II or worse congestive heart failure, or severe arrhythmias requiring medication, or a history of myocardial infarction within the past 12 months; Patients currently receiving immunosuppressive therapy; Known active major infections, or significant hematological, renal, metabolic, gastrointestinal, endocrine dysfunction, or other serious uncontrolled comorbid conditions, as determined by the investigator; Patients with hypersensitivity to any component of the investigational drugs; History of immunodeficiency, including positive HIV test results or other acquired or congenital immunodeficiency diseases, history of organ transplantation, or other immunologically related conditions requiring long-term oral steroid therapy; Other conditions deemed unsuitable for enrollment by the investigator.\n\nExclusion Criteria:\n\nPatients with a history of any other malignant diseases within the past 5 years are excluded, except for curatively treated skin cancer and cervical carcinoma in situ.\n\nPatients with a history of uncontrolled epilepsy, central nervous system diseases, or psychiatric disorders are excluded if, in the judgment of the investigator, these conditions may impair the ability to sign the informed consent form or affect the patient's compliance with drug treatment.\n\nClinically significant (active) cardiovascular disease is excluded, including symptomatic coronary artery disease, New York Heart Association (NYHA) Class II or worse congestive heart failure, severe arrhythmias requiring medication, or a history of myocardial infarction within the past 12 months.\n\nPatients currently receiving immunosuppressive therapy are excluded. Known active major infections are excluded, as are significant hematological, renal, metabolic, gastrointestinal, endocrine dysfunction, or other serious uncontrolled comorbid conditions, as determined by the investigator.\n\nPatients with hypersensitivity to any component of the investigational drugs are excluded.\n\nHistory of immunodeficiency is excluded, including positive HIV test results, other acquired or congenital immunodeficiency diseases, history of organ transplantation, or other immunologically related conditions requiring long-term oral steroid therapy.\n\nOther conditions deemed unsuitable for enrollment by the investigator are excluded.",{"count":285,"type":19},19,[52],"The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of \"PRaG-1\" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.",[246,25],"2025-06-08",{"date":291,"type":33},"2025-06-10",{"date":293,"type":19},"2025-06-15",{"date":295,"type":19},"2026-06-26",{"name":148,"class":40},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":41},"100584801","study-of-radiology-manipulator-work-validation-by-the-radiologist-100584801","NCT06894082","Study of Radiology Manipulator Work Validation by the Radiologist","COOPERATION BETWEEN THE MEDICAL ELECTRORADIOLOGY MANIPULATOR (MEM) AND THE RADIOLOGIST IN TUMOR IMAGING ASSESSMENTS: CIMER-IPC 2023-030","Cimer","Inclusion Criteria:\n\n* Male or female aged 18 and over\n* Patient included in a clinical research protocol in oncology for solid cancer including RECIST 1.1 interpretation\n* Disease measurable according to RECIST 1.1\n* Patient not objecting to study participation\n* Member of a social security scheme, or beneficiary of such a scheme.\n\nNon inclusion Criteria:\n\n* Patients with lymphoma or leukemia\n* Patient contraindicated to iodinated contrast media injection\n* Person in an emergency situation, adult subject to a legal protection measure (major under guardianship, curatorship or safeguard of justice), or unable to express, his\u002Fher non-opposition to participate in the study\n* Unable to undergo medical follow-up for geographical, social or psychological reasons.\n\nor psychological reasons.\n\nExclusion Criteria:\n\n* Patient with renal insufficiency or allergy during the trial no longer allowing injection of iodinated contrast medium\n* Patient refusing iodinated PDC injection during the study\n* Patient withdrawn from the study including scanner interpretation in Recist 1.1",{"count":306,"type":19},87,"The main objective of this study is to evaluate the pre-filling work on target and non-target lesions, and the detection of any new lesions reported by the MEM trained in protocol evaluations, in a structured table to prepare the radiologist's work in interpreting RECIST 1.1 scans.\n\nTo meet this objective, patients taking part in the CIMER study will first have been included in a research protocol requiring scans with RECIST 1.1 interpretation.\n\nThe Baseline examination will be performed and interpreted according to RECIST 1.1 without informing the radiologist performing the reading that the patient is included in the study, so as not to introduce an interpretation bias.\n\nDuring the first evaluation. The investigating MEM alone will carry out a preliminary analysis of the first evaluation and will present his results to the radiologist in charge of the evaluation, who will validate the conformity of the results.",[25],"2025-03-18",{"date":311,"type":33},"2025-03-25",{"date":313,"type":33},"2024-12-12",{"date":315,"type":19},"2027-05",{"name":317,"class":40},"Institut Paoli-Calmettes",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":107,"enrollmentInfo":325,"targetDuration":4,"studyType":20,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100572216","phase-1-a-phase-i-study-of-ak138d1-in-the-treatment-of-advanced-solid-tumors-100572216","NCT06730386","A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors","A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. The subject must sign the written informed consent form (ICF) voluntarily;\n2. At enrollment, aged ≥ 18 to ≤ 75 years, both males and females are eligible;\n3. ECOG performance status score of 0 or 1;\n4. Has a life expectancy of ≥ 3 months;\n5. Subjects who have histologically or cytologically diagnosed locally advanced or metastatic solid tumor, which Is refractory to or intolerant to standard treatment;\n6. At least 1 measurable lesion as per RECIST v1.1 that is suitable for repeated accurate measurement.\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. Prior human epidermal growth factor receptor 3 (HER3) -targeted therapies, including antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell immunotherapy (CAR-T), and others;\n2. Concomitant participation in another clinical study, unless it is a non-interventional clinical study or the follow-up period of an interventional study;\n3. Presence of active central nervous system (CNS) metastases.\n4. Patients with a history of non-infectious pneumonitis requiring systemic corticosteroid therapy; a history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis); currently suffering from ILD\u002Fpneumonitis or suspected of having such diseases based on imaging during screening;\n5. Live vaccines or attenuated live vaccines administered within 4 weeks prior to the first dose, or planned to be administered during the study; use of inactivated vaccines is allowed;\n6. Untreated subjects with active hepatitis B (HBsAg positive and HBV-DNA exceeding 1000 copies\u002FmL (200 IU\u002FmL) and above the lower limit of detection). For HBsAg-positive subjects, anti-hepatitis B therapy is required during the study; subjects with active hepatitis C (HCV antibody positive and HCV-RNA levels above the lower limit of detection) is also an exclusion;\n7. Known active pulmonary tuberculosis (TB); subjects with suspected active TB must undergo appropriate clinical assessment to rule out the presence of active disease;\n8. Active syphilis infection;\n9. Subjects with known allergy to any component of any study drug; and with a history of known severe hypersensitivity reactions to other monoclonal antibodies;\n10. Other reasons for ineligibility as evaluated by the investigator.",{"count":326,"type":19},100,[83],"This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.",[25],"2025-03-04",{"date":332,"type":33},"2025-03-06",{"date":334,"type":33},"2025-02-24",{"date":336,"type":19},"2028-08-30",{"name":193,"class":71},4,{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":20,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":41},"100574736","phase-1-a-study-of-hs-20124-in-patients-with-advanced-solid-tumors-100574736","NCT06763159","A Study of HS-20124 in Patients with Advanced Solid Tumors","A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20124 in Patients with Advanced Solid Tumors","Inclusion Criteria:\n\n1. At least age of 18 years at screening;\n2. Histologically or cytologically confirmed, locally advanced or metastatic solid tumors for which standard treatment either does not exist or has proven ineffective or unavailable or intolerable\n3. At least one extra-cranial measurable lesion according to RECIST 1\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\\~1\n5. Life expectancy \\>= 12 weeks\n6. Men or women should be using adequate contraceptive measures throughout the study;\n7. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential\n8. Signed and dated Informed Consent Form\n\nExclusion Criteria:\n\n1.Treatment with any of the following:\n\n1. Previous or current treatment with CDH6 targeted therapy\n2. Any cytotoxic chemotherapy and small molecule targeted anticancer drugs within 21 days or five half-livesprior to the first scheduled dose of HS-20124\n3. Prior treatment with a monoclonal antibody or investigational agents within 28 days prior to the first scheduled dose of HS-20124\n4. Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20124\n5. Major surgery within 4 weeks prior to the first scheduled dose of HS-20124 2. Subjects with previous or concurrent malignancies 3. Inadequate bone marrow reserve or organ dysfunction 4. Evidence of cardiovascular risk 5. Evidence of current severe or uncontrolled systemic diseases 6. Evidence of mucosal or internal bleeding within 1 month prior to the first scheduled dose of HS-20124 7. Severe infection within 4 weeks prior to the first scheduled dose of HS-20124 8. Subjects with current infectious diseases 9. History of neuropathy or mental disorders 10. Pregnant or lactating female 11. History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to HS-20124 or any of the components of HS-20124",{"count":347,"type":19},450,[83],"HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.",[25],"2025-01-01",{"date":353,"type":33},"2025-01-08",{"date":355,"type":33},"2024-10-30",{"date":357,"type":19},"2027-12-31",{"name":359,"class":71},"Hansoh BioMedical R&D Company",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":107,"enrollmentInfo":366,"targetDuration":4,"studyType":20,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":41},"100569701","early-phase-1-an-exploratory-clinical-study-to-evaluate-the-safety-tolerability-immune-response-and-preliminary-efficacy-of-lm103-injection-in-combination-with-pd-1-in-patients-with-advanced-solid-tumours-100569701","NCT06697665","An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n1. The expected survival time is not less than 3 months.\n2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.\n3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, cervical cancer\u002Fovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.\n4. The patient has lesions that can be used for surgical resection (\\>1.5 cm3) or biopsy puncture (no less than 6 lesions) for LM103 manufacturing.\n5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).\n6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.\n\nExclusion Criteria:\n\n1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).\n2. LM103 received systematic therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.\n3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).\n4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.",{"count":367,"type":19},10,[111],"This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours. The research treatment includes LM103 injection, IL-2 therapy, PD-1 therapy,fludarabine and cyclophosphamide.",[25],"2024-11-17",{"date":373,"type":33},"2024-11-20",{"date":375,"type":33},"2024-01-23",{"date":253,"type":19},{"name":378,"class":71},"Suzhou BlueHorse Therapeutics Co., Ltd.",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":15,"minAge":387,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":41},"100276905","elderly-cancer-patient-100276905","NCT02884375","Elderly CAncer Patient","Elderly Cancer Patient: ELCAPA Cohort Survey","ELCAPA","Inclusion Criteria:\n\n* Patient aged 70 years or older\n* Diagnosed cancer at all stage\n* Referred to a geriatrician for GA\n* Given oral non-opposition from patient or a legally mandated person\n\nExclusion Criteria:\n\n* Oral opposition","70 Years",{"count":389,"type":19},3000,"The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age. Cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. The heterogeneity of the older population in terms of comorbidities and functional status may explain the difficulty in establishing management recommendations.\n\nStudy hypothesis is that a geriatric consultation using Geriatric Assessment (GA) can evaluate patient's resource and strengths, in order to help oncologist to define the most effective treatment. The GA developed by geriatricians and recommended by the International Society of Geriatric Oncology (SIOG), is a multidimensional assessment of general health status; comorbidities; functional status; nutritional, cognitive, psychological, and social parameters; and medications. The GA uses validated geriatric scales to produce an inventory of problems, which can then serve to develop an individualized geriatric intervention plan; it may be an important step in selecting elderly patients for cancer screening and treatment.\n\nThe objectives are:\n\n* To assess the role of GA for decision making process for older patients with cancer\n* To identify geriatric and oncologic factors associated with overall survival, treatment feasibility, toxicities, morbidities\n* To develop and\u002For validate screening tests for frailty in geriatric oncology\n* To develop and validate frailty classifications\n\nMethod: The ELCAPA (ELderly CAncer PAtient) survey is a French multicentric prospective study that includes all patients age 70 years or older who has a diagnosis of solid cancer or hematologic malignancies in French hospitals",[392,25],"Hematologic Malignancies",[394,246,395,396,397],"Elderly","Geriatric assessment","Treatment","Epidemiology","2016-08-25",{"date":400,"type":19},"2016-08-31",{"date":402,"type":4},"2010-09",{"date":404,"type":19},"2027-11",{"name":406,"class":40},"Assistance Publique - Hôpitaux de Paris"]